US Bancorp’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-114
| Closed | -$4K | – | 4150 |
|
|
2021
Q1 | $4K | Hold |
114
| – | – | ﹤0.01% | 3585 |
|
|
2020
Q4 | $2K | Buy |
+114
| New | +$1.43K | ﹤0.01% | 3627 |
|
|
2019
Q1 | – | Sell |
-10
| Closed | – | – | 3691 |
|
|
2018
Q4 | $0 | Sell |
10
-65
| -87% | -$773 | ﹤0.01% | 3753 |
|
|
2018
Q3 | $1K | Sell |
75
-6
| -7% | -$89 | ﹤0.01% | 3602 |
|
|
2018
Q2 | $1K | Buy |
+81
| New | +$1.41K | ﹤0.01% | 3585 |
|
|
2017
Q4 | – | Sell |
-36
| Closed | -$1K | – | 3714 |
|
|
2017
Q3 | $1K | Hold |
36
| – | – | ﹤0.01% | 3536 |
|
|
2017
Q2 | $1K | Sell |
36
-21
| -37% | -$655 | ﹤0.01% | 3496 |
|
|
2017
Q1 | $2K | Buy |
+57
| New | +$2.51K | ﹤0.01% | 3424 |
|
|
2016
Q3 | – | Sell |
-731
| Closed | -$30K | – | 3664 |
|
|
2016
Q2 | $30K | Buy |
731
+28
| +4% | +$1.22K | ﹤0.01% | 2641 |
|
|
2016
Q1 | $29K | Buy |
703
+303
| +76% | +$10.4K | ﹤0.01% | 2626 |
|
|
2015
Q4 | $17K | Hold |
400
| – | – | ﹤0.01% | 2893 |
|
|
2015
Q3 | $6K | Hold |
400
| – | – | ﹤0.01% | 3220 |
|
|
2015
Q2 | $10K | Buy |
+400
| New | +$8.91K | ﹤0.01% | 3148 |
|
US Bancorp's FPRX Position: Q2 2021 in Review
US Bancorp sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 114 shares — an estimated $4K sold.
US Bancorp first reported a position in FPRX in Q2 2015 and held it in 13 quarters. The position peaked at $30K in Q2 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- US Bancorp reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- US Bancorp sold 114 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $4K.
- US Bancorp first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 13 quarters.
- US Bancorp's Five Prime Therapeutics, Inc. position peaked at $30K in Q2 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on US Bancorp's 13F filing for Q2 2021, filed 5 Aug 2021.